Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 141 for:    "eosinophilic esophagitis"

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03812575
Recruitment Status : Recruiting
First Posted : January 23, 2019
Last Update Posted : March 8, 2019
Sponsor:
Information provided by (Responsible Party):
Cristoniel Santos Abrenica, The University of Texas Health Science Center, Houston

Brief Summary:
The purpose of the study is to evaluate of the relationships between fractionated exhaled nitric oxide, disease activity, and symptom severity in patients with eosinophilic esophagitis compared to those without eosinophilic esophagitis.

Condition or disease
Eosinophilic Esophagitis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis
Actual Study Start Date : January 31, 2019
Estimated Primary Completion Date : July 28, 2019
Estimated Study Completion Date : July 28, 2019

Resource links provided by the National Library of Medicine


Group/Cohort
Active eosinophilic esophagitis
Eosinophilic esophagitis in remission
No eosinophilic esophagitis



Primary Outcome Measures :
  1. Fractionated exhaled nitric oxide (FeNO) level [ Time Frame: baseline (day of first endoscopy) ]
    The FeNO measurement will be performed using a hand-held analyzer, the NIOX MINO (Aerocrine, Sweden). During this non-invasive procedure the patient is asked to perform a 4-6 second single-breath exhalation into the NIOX MINO, which measures FeNO in 100s with an electrochemical sensor.

  2. Fractionated exhaled nitric oxide (FeNO) level [ Time Frame: at about 4-12 weeks (day of second clinic visit or endoscopy) ]
    The FeNO measurement will be performed using a hand-held analyzer, the NIOX MINO (Aerocrine, Sweden). During this non-invasive procedure the patient is asked to perform a 4-6 second single-breath exhalation into the NIOX MINO, which measures FeNO in 100s with an electrochemical sensor.


Secondary Outcome Measures :
  1. Esophageal eosinophil counts as assessed by biopsy [ Time Frame: baseline (day of first endoscopy) ]
  2. Esophageal eosinophil counts as assessed by biopsy [ Time Frame: at about 4-12 weeks (day of second clinic visit or endoscopy) ]
  3. Serum eosinophil counts as assessed by complete blood count (CBC) [ Time Frame: baseline (day of first endoscopy) ]
  4. Disease-related symptoms severity as assessed by Pediatric Eosinophilic Esophagitis Symptom Severity (PEESS) version 2.0 questionnaire [ Time Frame: baseline (day of first endoscopy) ]
    The range of total score is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms.

  5. Disease-related symptoms severity as assessed by Pediatric Eosinophilic Esophagitis Symptom Severity (PEESS) version 2.0 questionnaire [ Time Frame: at about 4-12 weeks (day of second clinic visit or endoscopy) ]
    The range of total score is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients will be recruited from the outpatient clinic of the Pediatric Gastroenterology Division of The University of Texas Health and Science Center at Houston.
Criteria

Inclusion Criteria:

  • Pediatric patient who will undergo esophagogastroduodenoscopy with biopsies at Children's Memorial Hermann Hospital, as part of the standard of care in the evaluation of EoE
  • Able to perform the single-breath exhalation for the hand-held analyzer, "NIOX VERO®" (Aerocrine, Sweden)
  • Signed informed consent by a parent or legal guardian
  • Signed assent form by the child/adolescent subjects 7-18 years of age

Exclusion Criteria:

  • Past medical history of asthma, allergic rhinitis, IBD, parasitic infection, hay fever and any exposure to smoking (including secondhand smoke) because these disorders are known to affect the FeNO levels
  • Active respiratory tract infections at the time of FeNO evaluation because this can affect the result of the FeNO as well
  • Asthma questionnaire and/or Spirometry test consistent with asthma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03812575


Contacts
Layout table for location contacts
Contact: Cristoniel Abrenica, MD (713) 500-5663 noeoehouston@gmail.com

Locations
Layout table for location information
United States, Texas
The University of Texas Health Science Center at Houston Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Investigators
Layout table for investigator information
Principal Investigator: Cristoniel Abrenica, MD The University of Texas Health Science Center, Houston

Layout table for additonal information
Responsible Party: Cristoniel Santos Abrenica, Fellow, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT03812575     History of Changes
Other Study ID Numbers: HCS-MS-18-1019
First Posted: January 23, 2019    Key Record Dates
Last Update Posted: March 8, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Eosinophilic Esophagitis
Esophagitis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents